Katrina Thornber, Author at European Medical Journal - Page 32 of 50

No Benefit from Chest Wall Irradiation in Intermediate-Risk Breast Cancer: SABCS 2024

Avoiding chest wall irradiation post-mastectomy is safe for most intermediate-risk breast cancer patients, improving quality of care.

The Role of Biomarkers in Frailty and Liver Health

Frailty has emerged as a therapeutic target in advanced chronic liver disease management, with non-pharmacological interventions showing promise.

Long-Term Success with Cyclophosphamide in Refractory Myasthenia Gravis

Cyclophosphamide offers rapid remission and long-term benefits in high-risk myasthenia gravis, reducing corticosteroid reliance and injectable therapies.

Obesity Linked to More Severe Symptoms and Higher Steroid Use in Polymyalgia Rheumatica

Obesity may worsen symptoms and increase glucocorticoid requirements in polymyalgia rheumatica, according to new research. Patients with obesity reported greater pain and fatigue and needed higher steroid doses over time despite similar inflammation levels.

Mifepristone-Misoprostol Reduces Treatment Failure in Early Pregnancy Loss

The addition of mifepristone to misoprostol for medical management of early pregnancy loss significantly reduces the rate of treatment failure.

70% of Young People Recover From Long COVID Within 2 Years

A new study highlights the enduring effects of post-COVID-19 condition on children and young people.

Gastric Metaplasia Linked to 19-Fold Cancer Risk in Caucasian Populations

The 10-year study challenges previous assumptions about gastric cancer risks in Western populations, particularly among Caucasian Americans.

High Processed Food Intake Linked to Active Psoriasis Risk

Individuals with active psoriasis displayed a lower proportion of females and were more likely to be obese.

Clopidogrel Outperforms Aspirin for Post-PCI Therapy

Clopidogrel reduces thrombotic and bleeding risks over aspirin after PCI, effective regardless of bleeding risk or complexity.

Advancing Survival in mHSPC with New Standards

Recent years have seen the international standard of care for mHSPC evolve to include androgen-deprivation therapy combined with docetaxel.